Lucinda Quan
Net worth: 227 035 $ as of 2024-05-30
Profile
Lucinda Y.
Quan is the founder.
She founded Aligos Therapeutics, Inc. in 2018 and served as the Chief Business Officer, EVP & General Counsel until 2023.
She also held former positions at Merck & Co., Inc. from 2016 to 2018 as the Executive Director-Business Development, at InterMune, Inc. from 2004 to 2013 as the VP-Legal Affairs & Associate General Counsel, and at Alios BioPharma, Inc. from 2013 to 2016 as the Vice President & Head-Legal Affairs.
Ms. Quan received her undergraduate and graduate degrees from the University of California, Los Angeles.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2023-09-07 | 384,805 ( 0.51% ) | 227 035 $ | 2024-05-30 |
Former positions of Lucinda Quan
| Companies | Position | End |
|---|---|---|
| ALIGOS THERAPEUTICS, INC. | Founder | 2023-11-30 |
| MERCK & CO., INC. | Corporate Officer/Principal | 2018-03-31 |
Alios BioPharma, Inc.
 Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | General Counsel | 2015-12-31 |
| INTERMUNE INC | General Counsel | 2013-10-31 |
Training of Lucinda Quan
| University of California, Los Angeles | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| ALIGOS THERAPEUTICS, INC. | Health Technology |
| MERCK & CO., INC. | Health Technology |
| Private companies | 2 |
|---|---|
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Health Technology |
InterMune, Inc.
 InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
- Stock Market
- Insiders
- Lucinda Quan
